Elevated levels of activin A in clinical and experimental pulmonary hypertension
1 Research Institute for Internal Medicine, Rikshospitalet University Hospital, 2 Institute for Experimental Medical Research, Ullevål University Hospital, 3 Department of Pulmonary Medicine, Ullevål University Hospital, 4 Center for Heart Failure Research, 5 Institute for Surgical Research, Rikshos...
Gespeichert in:
Veröffentlicht in: | Journal of applied physiology (1985) 2009-04, Vol.106 (4), p.1356-1364 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1 Research Institute for Internal Medicine, Rikshospitalet University Hospital, 2 Institute for Experimental Medical Research, Ullevål University Hospital, 3 Department of Pulmonary Medicine, Ullevål University Hospital, 4 Center for Heart Failure Research, 5 Institute for Surgical Research, Rikshospitalet University Hospital, 6 Medical Department, Diakonhjemmet Hospital, 7 Department of Endocrinology, Rikshospitalet University Hospital, 8 Department of Cardiology, Ullevål University Hospital, 9 Department of Cardiology, and 10 Section of Clinical Immunology and Infectious Diseases, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway
Submitted 4 June 2008
; accepted in final form 2 February 2009
Activin A, a member of the transforming growth factor (TGF)-β superfamily, is involved in regulation of tissue remodeling and inflammation. Herein, we wanted to explore a role for activin A in pulmonary hypertension (PH). Circulating levels of activin A and its binding protein follistatin were measured in patients with PH ( n = 47) and control subjects ( n = 14). To investigate synthesis and localization of pulmonary activin A, we utilized an experimental model of hypoxia-induced PH. In mouse lungs, we also explored signaling pathways that can be activated by activin A, such as phosphorylation of Smads, which are mediators of TGF-β signaling. Possible pathophysiological mechanisms initiated by activin A were explored by exposing pulmonary arterial smooth muscle cells in culture to this cytokine. Elevated levels of activin A and follistatin were found in patients with PH, and activin A levels were significantly related to mortality. Immunohistochemistry of lung autopsies from PH patients and lungs with experimental PH localized activin A primarily to alveolar macrophages and bronchial epithelial cells. Mice with PH exhibited increased pulmonary levels of mRNA for activin A and follistatin in the lungs, and also elevated pulmonary levels of phosphorylated Smad2. Finally, we found that activin A increased proliferation and induced gene expression of endothelin-1 and plasminogen activator inhibitor-1 in pulmonary artery smooth muscle cells, mediators that could contribute to vascular remodeling. Our findings in both clinical and experimental studies suggest a role for activin A in the development of various types of PH.
growth factors; inflammation; pathogenesis
Address for reprint requests and other correspondence: A. Yndestad, Research Institute for |
---|---|
ISSN: | 8750-7587 1522-1601 |
DOI: | 10.1152/japplphysiol.90719.2008 |